Revvity HTRF Hman Androgen Recetor Variant 7 Detection Kit, 500 Aay Point

Revvity The HTRF Androgen Recetor Variant 7 detection aay monitor the exreion of the Androgen Recetor lice Variant 7 (AR-V7), roviding inight into it reence, whether endogeno or overexreed, within vario cell. The Androgen Recetor i a nclear recetor that i activated y androgen hormone, inclding tetoterone (T) and Dihydrotetoterone (DHT). Androgen ind to the ligand inding domain of the Androgen Recetor, relting in recetor homodimerization and tranlocation to the ncle. Downtream gene exreion and ignaling athway are then activated, inclding the PI3KAKT athway. The gene exreion indced y the Androgen Recetor romote cell diviion, roliferation, differentiation, aotoi, and angiogenei. Dyreglation of the Androgen Recetor athway can lead to oncogenic henotye, with Androgen Recetor activation or exreion having een linked to condition ch a rotate cancer, reat cancer, gliolatoma, and other malignancie. Moreover, Androgen Recetor variant are exreed in vario hman cancer cell line. The Androgen Recetor Variant 7 (AR-V7) i a lice variant of the androgen recetor mRNA characterized y a trncated ligand-inding domain. It i contittively active and widely exreed in hman cancer cell line. Among the AR-V decried to date, AR-V7 i the mot extenively evalated and characterized, and everal lood-aed tet for AR-V7 have een develoed.Androgen Recetor and Variant 7 in articlar ha therefore ecome an imortant drg target for the harmacetical indtry. The develoment of PROTAC comond targeting the degradation of the Androgen Recetor i a olar theraetic trategy to target Androgen Recetor-oitive cancer.-PEGSK(Additional S&H Or Hazmat Fees May Apply)